A Comparison of Differences Between the Systemic Pharmacokinetics of Levobupivacaine and Ropivacaine During Continuous Epidural Infusion
Authors:
- Luciano PerottiLPLuciano Perotti
- Maria CusatoMCMaria Cusato
- Pablo IngelmoPIPablo Ingelmo
- Thekla Larissa NiebelTNThekla Larissa Niebel
- Marta SomainiMSMarta Somaini
- Francesca RivaFRFrancesca Riva
- Carmine TinelliCTCarmine Tinelli
- José De AndrésJAJosé De Andrés
- Guido FanelliGFGuido Fanelli
- Antonio BraschiABAntonio Braschi
- Mario RegazziMRMario Regazzi
- Massimo AllegriMAMassimo Allegri
Open Access
- 1 August 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 121 (2) , 348-356
Abstract
Epidural infusion of levobupivacaine and ropivacaine provides adequate postoperative pain management by minimizing side effects related to IV opioids and improving patient outcome. The safety profile of different drugs can be better estimated by comparing their pharmacokinetic profiles than by considering their objective side effects. Because levobupivacaine and ropivacaine have different pharmacokinetic properties, our aim was to investigate whether there is a difference in the pharmacokinetic variability of the 2 drugs in a homogeneous population undergoing continuous epidural infusion. This double-blind, multicenter, randomized, controlled trial study was designed to compare the pharmacokinetics of continuous thoracic epidural infusion of levobupivacaine 0.125% or ropivacaine 0.2% for postoperative pain management in adult patients who had undergone major abdominal, urological, or gynecological surgery. This study is focused on the evaluation of the coefficient of variation (CV) to assess the equivalence in the systemic exposure and interindividual variability between levobupivacaine and ropivacaine and, therefore, the possible differences in the predictability of the plasmatic concentrations of the 2 drugs during thoracic epidural infusion. One hundred eighty-one adults undergoing major abdominal surgery were enrolled in the study. Patients were randomized to receive an epidural infusion of levobupivacaine 0.125% + sufentanil 0.75 μg/mL or of ropivacaine 0.2% + sufentanil 0.75 μg/mL at 5 mL/h for 48 hours. The primary end point of this study was to analyze the variability of plasma concentration of levobupivacaine and ropivacaine via an area under the curve within a range of 15% of the CV during 48 hours of continuous epidural infusion. The CV shows how the concentration values of local anesthetics are scattered around the median concentration value, thus indicating the extent to which plasma concentration is predictable during infusion. Secondary end points were to assess the pharmacologic profile of the local anesthetics used in the study, including an analysis of mean peak plasma concentrations, and also to assess plasma clearance, side effects, pain intensity (measured with a verbal numeric ranging score, i.e., static Numeric Rating Scale [NRS] and dynamic NRS]), and the need for rescue doses. The comparison between the 2 CVs showed no statistical difference: the difference between area under the curve was within the range of 15%. The CV was 0.54 for levobupivacaine and 0.51 for ropivacaine (P = 0.725). The plasma concentrations of ropivacaine approached the Cmax significantly faster than those of levobupivacaine. Clearance of ropivacaine decreases with increasing patient age. There were no significant differences in NRS, dynamic NRS scores, the number of rescue doses, or in side effects between groups. Considering the CV, the interindividual variability of plasma concentration for levobupivacaine and ropivacaine is equivalent after thoracic epidural infusion in adults. We found a reduction in clearance of ropivacaine depending on patient age, but this finding could be the result of some limitations of our study. The steady-state concentration was not reached during the 48-hour infusion and the behavior of plasma concentrations of ropivacaine and levobupivacaine during continuous infusions lasting more than 48 hours remains to be investigated, because they could reach toxic levels. Finally, no differences in the clinical efficacy or in the incidence of adverse effects between groups were found for either local anesthetic.Keywords
This publication has 45 references indexed in Scilit:
- Successful treatment of ropivacaine-induced central nervous system toxicity by use of lipid emulsion: effect on total and unbound plasma fractionsJournal of Anesthesia, 2011
- LevobupivacaineDrugs, 2010
- Epidural space and regional anesthesiaEuropean journal of pain, 2009
- Population Pharmacokinetic–Pharmacodynamic Modeling of Epidural AnesthesiaAnesthesiology, 2008
- Ropivacaine-induced toxicity with overdose suspected after axillary brachial plexus blockJournal of Anesthesia, 2007
- The Effect of Age on the Systemic Absorption and Systemic Disposition of Ropivacaine after Epidural AdministrationAnesthesia & Analgesia, 2006
- Successful Resuscitation after Cardiovascular Collapse following Accidental Intravenous Infusion of Levobupivacaine during General AnesthesiaAnesthesiology, 2005
- RopivacaineDrugs, 2005
- Size, Myths and the Clinical Pharmacokinetics of Analgesia in Paediatric PatientsClinical Pharmacokinetics, 1997
- A simulation study of a test for the equality of the coefficients of variationCommunications in Statistics - Simulation and Computation, 1986